Alnylam Pharmaceuticals Inc.'s deals with Genzyme Corp. and Merck & Co. Inc. are designed to give the RNAi pioneer the wherewithal to deliver value to its shareholders for the next five to 10 years while remaining independent.

The Genzyme deal announced Monday will have the more immediate impact by boosting Alnylam's cash position, capabilities and valuation.